Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by Biotech777on Apr 09, 2014 12:05pm
154 Views
Post# 22430095

RE:RE:RE:RE:RE:RE:INTERESTING ARTICLE RE LIPID MANAGEMENT , DOSING START

RE:RE:RE:RE:RE:RE:INTERESTING ARTICLE RE LIPID MANAGEMENT , DOSING START
Guess it depends on what you mean by druggable? They can be formulated with phospholipids, but if by druggable you mean given orally, yes they can. Normally peptides longer then 3 or 4 amino acids in length will not be absorbed intact in the GI, however, that probelm has been solved in a few different ways. The most well known is simply using D-sided amino acids. Amino acids produced in the body are known as L-sided. This is why when you go the healthfood store and by say L-carnitine or something, the L just refers to the orinetation. D-sided amino acids have the same linear structure but use a mirror image. This mirror image shileds them from enyzymatic degradation in the GI and in plasma for an increased time.

While pepetides are considerably cheaper than full length proteins, they are still significantly more expensiveto manufacture  than small molucles like 208, so all things being equal, you would still rather have a smnall molecule from a company standpoint. From a aptient standpoint, that depends. Due to their larger size and know breakdown structures, peptides can have less side effects.
Bullboard Posts